JP2017538773A - 疾患の処置のための縮合二環式化合物 - Google Patents
疾患の処置のための縮合二環式化合物 Download PDFInfo
- Publication number
- JP2017538773A JP2017538773A JP2017533540A JP2017533540A JP2017538773A JP 2017538773 A JP2017538773 A JP 2017538773A JP 2017533540 A JP2017533540 A JP 2017533540A JP 2017533540 A JP2017533540 A JP 2017533540A JP 2017538773 A JP2017538773 A JP 2017538773A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- formula
- hydrogen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1(C2(*)*1)N(*)C(*)=C(*)c1c2c(C)c(*)[n]1* Chemical compound CC1(C2(*)*1)N(*)C(*)=C(*)c1c2c(C)c(*)[n]1* 0.000 description 41
- MDNNVKMUIHATNR-UHFFFAOYSA-N CCC(C)C(CC)N Chemical compound CCC(C)C(CC)N MDNNVKMUIHATNR-UHFFFAOYSA-N 0.000 description 2
- VAUARALLCYCPEB-UHFFFAOYSA-N CC(C)(c(c(nccc1)c1[nH]1)c1I)C#N Chemical compound CC(C)(c(c(nccc1)c1[nH]1)c1I)C#N VAUARALLCYCPEB-UHFFFAOYSA-N 0.000 description 1
- YXTRSJJMOFWVQN-UHFFFAOYSA-N CC(C)OC(C(c([nH]1)c(C(C)(C)C2)c3c1ncc(F)c3)=CN2C(c(cc1F)ccc1F)=O)=O Chemical compound CC(C)OC(C(c([nH]1)c(C(C)(C)C2)c3c1ncc(F)c3)=CN2C(c(cc1F)ccc1F)=O)=O YXTRSJJMOFWVQN-UHFFFAOYSA-N 0.000 description 1
- JQSKHADBHQVFCI-UHFFFAOYSA-N CC(C)OC(C1=CNCC(C)(C)C2=C1CCCc(nc1)c2cc1Cl)=O Chemical compound CC(C)OC(C1=CNCC(C)(C)C2=C1CCCc(nc1)c2cc1Cl)=O JQSKHADBHQVFCI-UHFFFAOYSA-N 0.000 description 1
- PZXOLNODCZLMQO-UHFFFAOYSA-N CC(C)OC(C1=CNCC(C)(C)c2c1[nH]c(nc1)c2cc1Cl)=O Chemical compound CC(C)OC(C1=CNCC(C)(C)c2c1[nH]c(nc1)c2cc1Cl)=O PZXOLNODCZLMQO-UHFFFAOYSA-N 0.000 description 1
- RLVZQSAKBAAURS-UHFFFAOYSA-N CC1C=Cc2cccnc2C1 Chemical compound CC1C=Cc2cccnc2C1 RLVZQSAKBAAURS-UHFFFAOYSA-N 0.000 description 1
- XPGRQQYMQLDFFX-UHFFFAOYSA-N CN(C)Cc(c1n2)c[nH]c1ccc2OC Chemical compound CN(C)Cc(c1n2)c[nH]c1ccc2OC XPGRQQYMQLDFFX-UHFFFAOYSA-N 0.000 description 1
- CQBKBEYZUHZJDG-LURJTMIESA-N C[C@@H]1C(F)=CC=C1C Chemical compound C[C@@H]1C(F)=CC=C1C CQBKBEYZUHZJDG-LURJTMIESA-N 0.000 description 1
- DCEIYGAVAZTMTN-UHFFFAOYSA-N C[Si](C)(C)C#Cc(c(N)c1)ncc1Cl Chemical compound C[Si](C)(C)C#Cc(c(N)c1)ncc1Cl DCEIYGAVAZTMTN-UHFFFAOYSA-N 0.000 description 1
- CDBBBCKWQIARQH-UHFFFAOYSA-N N#CCc1c[nH]c(nc2)c1cc2Cl Chemical compound N#CCc1c[nH]c(nc2)c1cc2Cl CDBBBCKWQIARQH-UHFFFAOYSA-N 0.000 description 1
- VLPUUGIMBDBPQS-UHFFFAOYSA-N N#CCc1c[nH]c2cc(Cl)cnc12 Chemical compound N#CCc1c[nH]c2cc(Cl)cnc12 VLPUUGIMBDBPQS-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N c(cc1)cc2c1[s]nn2 Chemical compound c(cc1)cc2c1[s]nn2 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N c(cc1)cc2c1cncc2 Chemical compound c(cc1)cc2c1cncc2 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- DVUBDHRTVYLIPA-UHFFFAOYSA-N c1c(cccc2)[n]2nc1 Chemical compound c1c(cccc2)[n]2nc1 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N c1c[nH]c2c1cccc2 Chemical compound c1c[nH]c2c1cccc2 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N c1c[s]c2c1cccc2 Chemical compound c1c[s]c2c1cccc2 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N c1cc2cncnc2cc1 Chemical compound c1cc2cncnc2cc1 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N c1ccc2nccnc2c1 Chemical compound c1ccc2nccnc2c1 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N c1ccncc1 Chemical compound c1ccncc1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N c1ccnnc1 Chemical compound c1ccnnc1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N c1cncnc1 Chemical compound c1cncnc1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N c1nc2ccccc2[nH]1 Chemical compound c1nc2ccccc2[nH]1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N c1nccnc1 Chemical compound c1nccnc1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N c1ncncn1 Chemical compound c1ncncn1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N c1ncnnc1 Chemical compound c1ncnnc1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095646P | 2014-12-22 | 2014-12-22 | |
| US62/095,646 | 2014-12-22 | ||
| PCT/IB2015/002549 WO2016103037A1 (en) | 2014-12-22 | 2015-12-21 | Fused bicyclic compounds for the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020167254A Division JP7089566B2 (ja) | 2014-12-22 | 2020-10-01 | 疾患の処置のための縮合二環式化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538773A true JP2017538773A (ja) | 2017-12-28 |
| JP2017538773A5 JP2017538773A5 (cg-RX-API-DMAC7.html) | 2019-02-07 |
Family
ID=55300724
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533540A Pending JP2017538773A (ja) | 2014-12-22 | 2015-12-21 | 疾患の処置のための縮合二環式化合物 |
| JP2020167254A Active JP7089566B2 (ja) | 2014-12-22 | 2020-10-01 | 疾患の処置のための縮合二環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020167254A Active JP7089566B2 (ja) | 2014-12-22 | 2020-10-01 | 疾患の処置のための縮合二環式化合物 |
Country Status (15)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017538773A (ja) * | 2014-12-22 | 2017-12-28 | アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． | 疾患の処置のための縮合二環式化合物 |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| EP3274350A1 (en) * | 2015-03-26 | 2018-01-31 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| TW201808283A (zh) * | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| CN110128432B (zh) * | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| JP2022541503A (ja) | 2019-07-23 | 2022-09-26 | ノバルティス アーゲー | Ｆｘｒアゴニストを使用した肝疾患の組み合わせ処置 |
| WO2021014349A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
| CN114630681A (zh) | 2019-09-03 | 2022-06-14 | 诺华股份有限公司 | 包含actrii受体拮抗剂的肝疾病或障碍的治疗 |
| WO2021053618A1 (en) | 2019-09-19 | 2021-03-25 | Novartis Ag | Treatment comprising fxr agonists |
| JP2022550312A (ja) | 2019-09-30 | 2022-12-01 | ノバルティス アーゲー | Ｆｘｒアゴニストの使用を含む処置 |
| KR20220119424A (ko) | 2019-12-20 | 2022-08-29 | 노파르티스 아게 | 인테그린 억제제를 사용한 간 질환의 조합 치료 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
| US12404261B2 (en) | 2020-12-22 | 2025-09-02 | Novartis Ag | Compounds and compositions for treating conditions associated with cGAS |
| EP4267571A1 (en) | 2020-12-22 | 2023-11-01 | Novartis AG | Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4679517B2 (ja) * | 2003-07-23 | 2011-04-27 | エグゼリクシス， インコーポレイテッド | 薬剤としてのアゼピン誘導体 |
| US20090203577A1 (en) * | 2005-12-15 | 2009-08-13 | Exelixis, Inc. | Azepinoindole Derivatives As Pharmaceutical Agents |
| JP2017538773A (ja) * | 2014-12-22 | 2017-12-28 | アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． | 疾患の処置のための縮合二環式化合物 |
-
2015
- 2015-12-21 JP JP2017533540A patent/JP2017538773A/ja active Pending
- 2015-12-21 EP EP15831230.6A patent/EP3237419B1/en not_active Not-in-force
- 2015-12-21 KR KR1020177020205A patent/KR20170117030A/ko not_active Abandoned
- 2015-12-21 AU AU2015370588A patent/AU2015370588B2/en not_active Ceased
- 2015-12-21 CA CA2971755A patent/CA2971755A1/en active Pending
- 2015-12-21 CN CN201580076617.4A patent/CN107438612A/zh active Pending
- 2015-12-21 RU RU2017126128A patent/RU2741387C2/ru active
- 2015-12-21 WO PCT/IB2015/002549 patent/WO2016103037A1/en not_active Ceased
- 2015-12-21 MX MX2017008456A patent/MX369623B/es active IP Right Grant
- 2015-12-21 RU RU2021100040A patent/RU2021100040A/ru not_active Application Discontinuation
- 2015-12-21 SG SG11201704770YA patent/SG11201704770YA/en unknown
- 2015-12-21 BR BR112017013568A patent/BR112017013568A2/pt not_active Application Discontinuation
-
2017
- 2017-06-12 IL IL252849A patent/IL252849B/en unknown
- 2017-06-22 CL CL2017001661A patent/CL2017001661A1/es unknown
- 2017-06-22 US US15/630,189 patent/US10167294B2/en active Active
- 2017-07-17 CO CONC2017/0007121A patent/CO2017007121A2/es unknown
-
2018
- 2018-12-31 US US16/237,017 patent/US10793577B2/en active Active
-
2020
- 2020-09-17 US US17/024,095 patent/US20210139490A1/en not_active Abandoned
- 2020-10-01 JP JP2020167254A patent/JP7089566B2/ja active Active
- 2020-10-13 AU AU2020256336A patent/AU2020256336A1/en not_active Abandoned
-
2023
- 2023-05-02 US US18/311,171 patent/US20240025914A1/en not_active Abandoned
-
2024
- 2024-10-24 US US18/925,911 patent/US20250206753A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7089566B2 (ja) | 疾患の処置のための縮合二環式化合物 | |
| US20250171446A1 (en) | Fused bicyclic compounds for the treatment of disease | |
| JP6843061B2 (ja) | 疾患治療のための縮合二環化合物 | |
| JP2019520335A (ja) | 疾患治療用の縮合二環式化合物 | |
| HK1245795B (en) | Fused bicyclic compounds for the treatment of disease | |
| HK1244802B (en) | Fused bicyclic compounds for the treatment of disease | |
| BR112017010627B1 (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181220 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191029 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200129 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200602 |